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Abstract
Background: Hyperhomocysteinemia (HHcy) is an independent risk factor for various cardiovascular diseases. Animal
studies have shown that homocysteine (Hcy) inhibits hepatic expression of apolipoprotein AI (apoAI). Our recent
clinical study showed that increased plasma Hcy levels were associated with decreased apoAI levels in patients with
impaired glucose tolerance. In this study, we assessed a potential association between Hcy and apoAI levels in normal
healthy people.
Methods: A total of 1768 normal healthy individuals were divided into two groups: the control group (subjects
without HHcy) and the HHcy group (subjects with HHcy).
Results: HHcy subjects exhibited significantly lower high-density lipoprotein cholesterol (HDL-C) and apoAI levels than
the control group (HDL-C: 1.18 ± 0.25 vs. 1.29 ± 0.32 mmol/L; apoAI: 1.38 ± 0.19 vs. 1.47 ± 0.25 g/L; all P < 0.01).
Plasma Hcy levels were negatively associated with HDL-C and apoAI levels after adjustments for age, BMI and
TG (HDL-C: r = –0.10; apoAI: r = –0.11; all P < 0.05). Multivariate regression analysis showed that the plasma Hcy
levels were an independent influencing factor for apoAI (β = –0.065, P < 0.05).
Conclusions: Increased plasma Hcy levels were associated with decreased apoAI levels in normal healthy
people, and the inhibition of apoAI synthesis might be a mechanism through which Hcy is linked with the
development of atherosclerosis in HHcy subjects.
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Background
Homocysteine (Hcy) is an intermediate of methionine me-
tabolism [1]. Some genetic defects and nutritional defi-
ciencies of B vitamins will cause elevated plasma Hcy
levels, which is defined as hyperhomocysteinemia (HHcy)
[1, 2]. HHcy has been widely proposed to be an independ-
ent risk factor for various cardiovascular diseases [3].
However, thus far, the precise mechanisms of how Hcy in-
terferes with cardiovascular systems have not yet been re-
vealed. In our previous studies, patients with acute
coronary syndrome had increased plasma Hcy levels and
HHcy subjects showed significant coronary endothelial
dysfunction [4, 5]. Hcy increased the expression of mono-
cyte chemoattractant protein-1 and promoted the gener-
ation of reactive oxygen species in human monocytes [6].
In white adipocytes, Hcy induced endoplasmic reticulum
stress, unregulated the expression of resistin, and further
caused insulin resistance [7, 8].
High-density lipoprotein (HDL) is a good lipoprotein
with cardiovascular protective effects due to its anti-
atherosclerotic, anti-inflammatory and anti-oxidative mech-
anisms [9]. ApoAI is a major component of HDL [10]. Our
recent clinical study showed that increased plasma Hcy
levels were associated with decreased apoAI levels in pa-
tients with impaired glucose tolerance (IGT) [11]. Previous
research in male patients with coronary artery disease also
demonstrated this negative correlation between Hcy and
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apoAI [12]. However, the associations between Hcy
and apoAI levels in normal healthy people have not
been well-characterized. In this study, we assessed the




We enrolled 1768 normal healthy individuals over the
age of 20 years who had undergone a routine physical
examination at Beijing Chao-yang Hospital Affiliated to
Capital Medical University from March 2012 to October
2014. Oral glucose tolerance tests (OGTT) and blood
pressure measurements were performed at screening. In-
dividuals with hypertension, coronary artery disease, dia-
betes, pre-diabetes, liver or renal function impairment,
infectious disease, systemic inflammatory disease or can-
cer were excluded. No subject took lipid-lowering agents
or vitamins. HHcy was defined by the plasma Hcy level
>15 μmol/L [2]. All participants were divided into two
groups: the control group (subjects without HHcy) and
HHcy group (subjects with HHcy). All enrolled subjects
provided written informed consent. The protocol of this
study was approved by the Ethics Committee of the
Beijing Chao-yang Hospital Affiliated to Capital Medical
University.
Clinical and biochemical measurements
A standard questionnaire was used to collect informa-
tion about the patients’ health status and medications.
Height and weight were measured to the nearest 0.1 cm
and 0.1 kg, respectively, by the same trained group.
Blood pressure was measured from the non-dominant
arm in a seated position after a ten-minute rest using
a sphygmomanometer. Venous blood samples were
obtained after overnight fasting. Plasma samples of all
participants were stored at –80 °C. High-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), triglyceride (TG), total choles-
terol (TC) levels were measured by colorimetric en-
zymatic assays using an autoanalyzer (Hitachi 7170).
Plasma TC was measured by an enzymatic cholesterol oxi-
dase reaction, TG by a glycerol lipase oxidase reaction,
and HDL-C and LDL-C were measured by the direct
assay. ApoAI and apolipoprotein B (apoB) were analyzed
with immune turbidimetry. Hcy, fasting blood glucose
(FBG), and fasting insulin (FINS) levels were measured at
the central chemistry laboratory in Beijing Chao-yang
Hospital Affiliated to Capital Medical University. Plasma
Hcy levels were measured by the clinical chemistry, FBG
by the glucose oxidase method, and FINS were measured
by the chemiluminescence method. Body mass index
(BMI) was calculated as the weight in kilograms divided
by the height in meters squared. Homeostasis model
assessment of insulin resistance (HOMA-IR) was per-
formed to evaluate insulin resistance according to the fol-
lowing formula: HOMA-IR = [FINS (μIU/mL) * FBG
(mmol/L)/22.5] [13].
Statistical methods
Normally distributed variables were expressed as the
mean ± standard deviation (SD), while variables with a
skewed distribution, including TG, FINS and HOMA-
IR, were given as the median and upper and lower
quartiles. Variables that were not normally distributed
were log-transformed before analysis. The proportions
were analyzed using chi-square tests. We also per-
formed Pearson and Spearman correlation analyses.
Multivariate analysis was used to evaluate the correl-
ation. All statistical analyses were performed with
SPSS 17.0 (SPSS, Inc., Chicago, IL), and the results
were considered statistically significant with two-tailed
analyses, P < 0.05.
Results
Clinical characteristics of the control and HHcy groups
The clinical characteristics of participants were summa-
rized in Table 1. The control and HHcy groups did not
significantly differ in age, gender, BMI, SBP and DBP. The
levels of FBG, FINS and HOMA-IR were also statistically
the same between the two groups. HHcy subjects showed
higher TG and lower HDL-C and apoAI levels compared
to controls [TG: 1.28 (0.88–1.97) vs. 1.12 (0.76–1.71)
mmol/L; HDL-C: 1.18 ± 0.25 vs. 1.29 ± 0.32 mmol/L;
apoAI: 1.38 ± 0.19 vs. 1.47 ± 0.25 g/L; all P < 0.01]. How-
ever, there was no significant difference in the TC, LDL-C
and ApoB levels between the two groups.
Correlation between plasma Hcy and the levels of apoAI
or other lipid profiles
Hcy was negatively correlated with the levels of HDL-C
and apoAI (HDL-C: r = –0.22, P < 0.01, 95 % confidence
interval –0.27 to –0.16; Fig. 1a) (apoAI: r = –0.19, P <
0.01, 95 % confidence interval –0.24 to –0.13; Fig. 1b),
and this negative correlation was observed after adjust-
ing for age, BMI and TG levels (HDL-C: r = –0.10;
apoAI: r = –0.11; all P < 0.05). We also found a positive
correlation between Hcy and the levels of TG and LDL-
C (TG: r = 0.14, P < 0.01, 95 % confidence interval 0.08
to 0.19) (LDL-C: r = 0.07, P < 0.01, 95 % confidence
interval 0.02 to 0.12); however, these correlations disap-
peared after adjustments for age and BMI.
Correlation between plasma Hcy and other metabolic
parameters
In all participants, we did not find a correlation between
Hcy and other metabolic parameters, including age,
BMI, SBP, DBP, FBG, FINS and HOMA-IR. However,
Wang et al. BMC Cardiovascular Disorders  (2016) 16:10 Page 2 of 5
Hcy was positively correlated with the levels of SBP and
DBP in the HHcy group (SBP: r = 0.12, P < 0.01, 95 %
confidence interval 0.07 to 0.17) (DBP: r = 0.14, P < 0.01,
95 % confidence interval 0. 08 to 0.19), and these corre-
lations remained even after adjusting for age and BMI
levels (SBP: r = 0.09; DBP: r = 0.10; all P < 0.05).
Multivariate stepwise regression analysis
To further evaluate the relationship between plasma
homocysteine and apoAI levels, we performed a multi-
variate regression analysis, including age, gender, BMI,
TG, Hcy and HOMA-IR. We found that plasma Hcy
levels were an independent influencing factor for apoAI
levels (β = –0.065, P < 0.05).
Discussion
In the present study, we assessed the potential associ-
ation between Hcy and apoAI levels in normal healthy
people. HHcy subjects exhibited significantly lower
HDL-C and apoAI levels than the control group. The
plasma Hcy levels were negatively associated with HDL-
C and apoAI levels after adjusting for age, BMI and TG.
Multivariate regression analysis showed that the plasma
Hcy level was an independent influencing factor for
apoAI.
HHcy is often associated with essential hypertension
[14]. Our previous studies showed that IGT patients with
HHcy had a higher prevalence of essential hypertension
[11]. HHcy increased blood pressure mediated through
the disruption of the bioavailability of tetrahydrobiopterin
and caused vascular endothelial dysfunction [14]. In
the present study, we observed healthy participants
without essential hypertension and found that Hcy
was positively correlated with the SBP and DBP levels
in the HHcy group. Subjects with a high-normal
blood pressure exhibited decreased artery elastic func-
tion and endothelial dysfunction [15, 16]. Thus, HHcy
may potentially enhance the levels of blood pressure
even within the normal range, and elevated blood
pressure is one factor that is likely to mediate cardio-
vascular disease in HHcy patients.
Our previous studies showed that Hcy contributes to
insulin resistance by inducing endoplasmic reticulum
stress, upregulating the expression of resistin, and inter-
rupting the phosphorylation of insulin receptor tyrosine
kinase [17]. In IGT patients, plasma Hcy levels are posi-
tively related to HOMA-IR [11]. Hypertensive patients
with HHcy had significant insulin resistance compared
to patients without HHcy [5]. However, in the present
study, there was no correlation between Hcy and
HOMA-IR not only in all of the participants but also in
the HHcy subjects. Insulin resistance is associated with
obesity, dyslipidemia and hypertension and other meta-
bolic risk factors [18]. IGT and hypertensive patients had
obvious metabolic disorders [19]; however, the present
study investigated normal healthy people who did not
have hypertension, diabetes and other overt metabolic
diseases. Thus, it might suggest that HHcy had a syner-
gistic promoting effect on insulin resistance with meta-
bolic risk factors, but HHcy had a weaker effect by itself
Table 1 Baseline characteristics of the control and HHcy groups
Parameters Control group (n = 1412) HHcy group (n = 356)
Age, y 41.11 ± 11.44 41.25 ± 12.25
Gender, Males/Females 790/622 196/160
BMI, kg/m2 24.33 ± 3.44 24.68 ± 3.13
SBP, mmHg 120.34 ± 11.26 121.35 ± 11.19
DBP, mmHg 73.04 ± 8.65 73.72 ± 8.89
TC, mmol/L 4.89 ± 0.90 4.87 ± 0.85
LDL-C, mmol/L 2.83 ± 0.73 2.90 ± 0.71
HDL-C, mmol/L 1.29 ± 0.32 1.18 ± 0.25**
TG, mmol/L 1.12 (0.76–1.71) 1.28 (0.88–1.97)**
apoAI, g/L 1.47 ± 0.25 1.38 ± 0.19**
apoB, g/L 0.87 ± 0.20 0.90 ± 0.20
FBG, mmol/L 5.34 ± 0.36 5.38 ± 0.35
FINS, μIU/mL 11.25 (7.40–16.16) 11.41 (8.39–16.40)
HOMA-IR 2.68 (1.74–3.87) 2.72 (1.97–4.01)
Homocysteine, μmol/L 11.04 ± 1.81 26.53 ± 13.68**
Data are means ± SD unless indicated otherwise. TG, FINS and HOMA-IR are shown as median and range. HHcy: hyperhomocysteinemia; BMI: body mass index; SBP: systolic
blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein
cholesterol; TG: triglyceride; apoAI: apolipoprotein AI; apoB: apolipoprotein B; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance. * significantly
different at P< 0.05 vs control; ** significantly different at P< 0.01 vs control
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on insulin resistance compared to hypertension, diabetes
and obesity.
HDL is a lipoprotein that is produced in the liver [9]. It
has anti-atherogenic properties by transporting cholesterol
from cells into peripheral tissues, reducing oxidative stress
and suppressing inflammatory pathways [9]. ApoAI is
a major functional component of HDL and is exten-
sively involved in the cardiovascular protective effects
of HDL [10]. Transgenic over-expression of apoAI mice
exhibit elevated plasma HDL-C levels and reduced vascu-
lar lesions [20]. Low apoAI (HDL-C) levels are a risk fac-
tor for atherosclerosis [9, 21]. However, the underlying
mechanism of low apoAI (HDL-C) levels still remains un-
known. Some factors, including obesity and smoking, have
been reported to reduce HDL-C and apoAI levels
[22]. Recent studies have presented a correlation be-
tween Hcy and apoAI. Recent animal and in vitro cell
studies have also demonstrated that Hcy suppresses
hepatic apoAI expression via the peroxisome prolif-
erator activated receptor α (PPARα) - apoAI pathway
[12, 23, 24]. Moreover, Hcy could decrease the tran-
scription of apoAI by stimulating nuclear factor κB
(NF-κB) and apoAI regulatory protein-1 (ARP-1) [19, 25].
Decreased plasma and hepatic expression levels of
apoAI have also been observed in animal models of
HHcy [12, 26]. Data from population studies in IGT
patients and male patients with coronary artery dis-
ease showed that Hcy levels are negatively correlated
with apoAI levels [12]. In the present study, plasma
Hcy levels were negatively associated with the HDL-C and
apoAI levels in normal healthy people, and plasma Hcy
levels were an independent influencing factor for apoAI
levels. Thus, it might suggest that HHcy is involved in the
development of low plasma levels of apoAI and HDL-C in
healthy people, and the inhibition of apoAI synthesis is a
subsequent mechanism through which Hcy is linked to
atherosclerosis development in HHcy patients. However,
inconsistently, a recent study showed that the plasma fol-
ate, but not Hcy, is associated with apoAI levels in a non-
fortified population [27]. One possible explanation for this
opposing result is that not all participants in that study
were fasting at the time of blood sampling, and the levels
of Hcy, folate and blood lipid may be influenced by eating
[27]. Unfortunately, our study did not assess the serum
folate levels of the participants. We will address this issue
in our further research.
Our study has several limitations. The major limitation
was that we did not assess the serum folates and MTHFR
polymorphisms (677C >T and 1298A >C) which had been
demonstrated as the determinant of the plasma Hcy levels.
Additionally, as a cross-sectional study, it is hard to confirm
causality. Further prospective or intervention researches are
needed to evaluate the potential association between Hcy
and apoAI levels.
Conclusions
In conclusion, increased plasma Hcy levels were associ-
ated with decreased apoAI levels in normal healthy
people, and the inhibition of apoAI synthesis might be a
mechanism through which Hcy is linked with the devel-
opment of atherosclerosis in HHcy subjects. Further re-
searches are needed to evaluate the potential association
between Hcy and apoAI levels.
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